Combining Targeted Biological Agents with Radiotherapy: Current Status and Future Directions

Combining Targeted Biological Agents with Radiotherapy: Current Status and Future Directions

by William Small Jr., William Dr.Small
     
 

View All Available Formats & Editions

Radiotherapy plays an integral role in cancer treatment. Approximately 60% of cancer patients will receive radiotherapy at some point in their treatment. A major improvement in patient outcomes occurs with the use of combined chemotherapy and radiotherapy. The combination of targeted biological agents with radiotherapy is the latest cutting-edge extension in cancer

Overview

Radiotherapy plays an integral role in cancer treatment. Approximately 60% of cancer patients will receive radiotherapy at some point in their treatment. A major improvement in patient outcomes occurs with the use of combined chemotherapy and radiotherapy. The combination of targeted biological agents with radiotherapy is the latest cutting-edge extension in cancer therapy for radiation oncologists.

Combining Targeted Biological Agents with Radiotherapy: Current Status and Future Directions is an overview of the current state of clinical and pre-clinical research in combining radiotherapy with targeted biological agents to fight cancer. The text provides a general overview of targeted agents, reviews the current clinical trials, and includes a look at the future of this state-of-the-art practice.

This book begins with a general overview of the topic, including an introduction to the subject; the basic science rationale behind the two most important current targeted agents: epidermal growth factor (EGFR) receptors and vascular epithelial growth factor (VEGF) receptors; the dermatologic manifestations of targeted agents; and an introduction to radioimmunotherapy a treatment that has the ability to combine targeted agents directly with radiotherapy. The second half of the book focuses on specific disease sites, including malignant gliomas, head and neck, lung, pancreatic, cervical, and endometrial cancers.

Biologically targeted agents promise to be the next significant breakthrough in cancer therapy. Written by leading experts in the field, Combining Targeted Biological Agents with Radiotherapy is a comprehensive evaluation of the entire field.

Editorial Reviews

Reviewer:James G. Douglas, MD, MS(University of Washington Medical Center)
Description:This relatively brief work examines the currently available molecular targeting agents and their interactions with irradiation. The basic science and mechanisms underlying the targeted agents are described, followed by discussions of relevant clinical trials organized by organ system.
Purpose:The book was written to "review both the basic science and current clinical status of combining targeted biologic agents with radiotherapy" as stated by the authors. The book for the most part achieves these objectives, which are certainly important concepts for radiation oncologists to grasp.
Audience:The authors do not clearly state their specific audience, but it can be inferred that the book is directed at radiation oncologists and medical oncologists who use combined modality therapy. The authors are experts in the field of molecular targeting and clinical trials.
Features:The initial three chapters describe the basic science concepts that form the basis for the use of biological targeting and describe the various pathways involved in the major signaling pathways surmised to be involved in cellular growth regulation and response to noxious stimuli. The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) signaling pathways are described in detail, each in a separate chapter. The remainder of the book deals with clinical uses and potential uses as well as deleterious side effects of targeting agents used as single modalities or combined with irradiation and/or cytotoxic agents.
Assessment:The book suffers at times from being overly technical in its descriptions of the various signaling pathways. The presentation in the first three chapters would have been improved by well placed figures that visually showed the pathways and the interactive molecules and gene products. In fact, the most useful figure does not appear until the eighth chapter, and it is of relatively poor quality. The more clinically related chapters do offer comprehensive reviews of current studies and planned studies and are generally well written.

Product Details

ISBN-13:
9781935281009
Publisher:
Springer Publishing Company
Publication date:
06/03/2008
Sold by:
Barnes & Noble
Format:
NOOK Book
Pages:
448
File size:
2 MB

Meet the Author

William Small, Jr, MD is Professor of Radiation Oncology and Vice-Chairman of the Department of Radiation Oncology at Northwestern University. He is the Associate Medical Director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and serves on the editorial board of the American Journal of Hematology/Oncology Review and Cancer News.

Customer Reviews

Average Review:

Write a Review

and post it to your social network

     

Most Helpful Customer Reviews

See all customer reviews >